Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Acevedo

Orthopaedic Surgery Jacksonville, FL Medical Doctor

NPI 1710969225 CMS profile 214379

2627 Riverside Ave, Suite 300, Jacksonville, FL 32204

Open in the dashboard

General payments

$3,273,191

633 records reported · program years 2019–2025

Research payments

$4,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jorge Acevedo of Jacksonville, FL is reported in the CMS Open Payments database as having received $3,273,191 across 633 general payments and $4,500 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $721,993 71
2024 General $593,336 58
2023 General $578,000 105
2022 General $465,649 79
2022 Research $4,500 1
2021 General $363,724 69
2020 General $253,703 61
2019 General $296,787 190

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Acevedo
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jorge Acevedo were reported at $721,993. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jorge Acevedo Orthopaedic Surgery median Middle half National median
2019 $296,787 $644 $140–$2,844 $163
2020 $253,703 $312 $75–$1,860 $114
2021 $363,724 $520 $117–$2,495 $132
2022 $465,649 $598 $128–$2,731 $149
2023 $578,000 $461 $128–$2,264 $160
2024 $593,336 $497 $134–$2,475 $164
2025 $721,993 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $3,265,897 565 payments
  2. Team 1, LLC $3,840 5 payments
  3. Medline Industries, Inc. $1,364 7 payments
  4. Stryker Corporation $463 3 payments
  5. Integra LifeSciences Corporation $286 3 payments
  6. Horizon Therapeutics plc $255 17 payments
  7. Alpha Orthopedic Systems $166 3 payments
  8. Exactech, Inc. $154 1 payment
  9. Janssen Pharmaceuticals, Inc $138 7 payments
  10. Wright Medical Technology, Inc. $130 2 payments
  11. Other $497 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,640,765 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $416,749 105 payments
  3. Consulting Fee $150,940 122 payments
  4. Travel and Lodging $54,805 149 payments
  5. Food and Beverage $7,643 225 payments
  6. Education $2,013 2 payments
  7. Long term medical supply or device loan $181 1 payment
  8. Gift $95 1 payment
Products named General payments · program years 2019–2025
  1. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - IB Ligament Augmentation - IB 2.0 $1,701,177 11 payments
  2. Arthrex Foot & Ankle and Trauma - Implants - Core Metal - Bunion - Beveled Screws $771,886 5 payments
  3. ARTHREX Distal Extremities - Implants - Soft Tissue - Ib Ligament Augmentation $686,008 8 payments
  4. ARTHREX Distal Extremities - Implants - Soft Tissue - Ib Ligament Augmentation $686,008 8 payments
  5. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - Achilles - MIS SpeedBridge $618,266 4 payments
  6. ARTHREX Distal Extremities - Implants - Soft Tissue - Ib Ligament Augmentation $615,439 7 payments
  7. ARTHREX Distal Extremities - Implants - Soft Tissue - Ib Ligament Augmentation $585,284 7 payments
  8. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - IB Ligament Augmentation $534,913 4 payments
  9. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - IB Ligament Augmentation $534,913 4 payments
  10. Arthrex Foot & Ankle and Trauma - Implants - Soft Tissue - IB Ligament Augmentation $534,913 4 payments
  11. Other $5,951,024 161 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Arthrex, Inc. $4,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

313

Median for Orthopedic Surgery: 203

Drug cost

$12,496

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Calcipotriene Generic 20 $4,398
Lidocaine Generic 83 $3,644
Ciclopirox Generic 32 $3,202
Meloxicam Generic 118 $721
Ketoconazole Generic 14 $212
Gabapentin Generic 22 $161
Celecoxib Generic 24 $158

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$1,322,527

Of which drugs: $1,125,899

Medicare patients

682

Average age 73

Services billed

4,321

445 women, 237 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 31%
Ischemic heart disease 27%
Depression 24%
Chronic kidney disease 21%
Osteoporosis 17%
COPD 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 117 760 $573

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $22
$22 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

634 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record